Conventional dose melphalan is inactive in XXXX : results of an Eastern Cooperative Oncology Group Study (E1687).

@entity1 @entity204 @entity320 @entity3601
Despite reports that i.v. melphalan is active in the settings of conditioning regimens utilizing high-dose chemotherapy for autologous bone marrow transplantation and in isolated limb perfusion for the treatment of @entity320 , its activity at conventional doses has never been defined in this disease. We conducted a phase II study of conventional-dose i.v. @entity3601 (30 mg/m2) in 17 @entity1 with @entity320 . All @entity1 were previously untreated with chemotherapy with performance status 0, 1 or 2. Forty-seven cycles were given with a median of two cycles. One @entity1 was not evaluable due to @entity204 . There were no responses in the 16 @entity1 , resulting in a 0% response rate (95% confidence interval = 0-17%). We conclude that conventional-dose melphalan by i.v. administration has no appreciable activity in @entity1 with metastatic @entity320 .
